Glooko to Expand EMEA CGM Connectivity with Roche Accu-Chek® SmartGuide Integration

Audio By Carbonatix

GOTHENBURG, Sweden--(BUSINESS WIRE)--Mar 10, 2026--

Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing challenges of glycemic safety and diabetes management across care settings, today announced that the Glooko platform will integrate with the Roche Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution across select European countries, subject to local availability.*

This integration will enable people using the Accu-Chek SmartGuide CGM to bring their CGM data into Glooko, alongside data from other connected diabetes and health monitoring devices. This can reduce the administrative burden for healthcare teams, allow for the viewing of key insights in one place, and support effective collaboration between patient visits.

Accu-Chek SmartGuide is Roche’s AI-enabled CGM solution designed to provide real-time glucose readings and predictive insights across multiple timeframes. The system includes the Accu-Chek SmartGuide sensor and an application to view and analyse CGM glucose values and predictions. With an all-in-one applicator and 14-day wear time, Accu-Chek SmartGuide is designed for people living with diabetes, 18 years of age and older. Built-in predictive capabilities help users anticipate glucose trends, including forecasts up to two hours ahead and overnight risk insights, supporting proactive diabetes management.

“Diabetes data is only powerful when it’s accessible, connected, and easy to act on,” said Mike Alvarez, Chief Executive Officer of Glooko. “By integrating Roche’s Accu-Chek SmartGuide CGM into the Glooko platform, we’re expanding choice for people with diabetes and clinicians. Now, they can bring Accu-Chek SmartGuide CGM data together with the rest of the patient’s health and medication therapy context, in a single experience designed to support better, more informed decisions.”

Glooko is the first diabetes data management platform outside of Roche’s ecosystem that will integrate with the Accu-Chek SmartGuide CGM. The integration is designed to help address a common challenge in diabetes care: data that lives in separate device-specific apps and portals, making it harder for patients and clinicians to see the full picture.

The Accu-Chek SmartGuide CGM integration will be available on the Glooko platform in key markets across Europe over the coming weeks, subject to country availability and local regulatory and market requirements. Healthcare organizations can contact their Glooko representative for details.

About Glooko

Glooko, Inc. is a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum. Glooko is uniquely positioned to be the enterprise partner of choice for healthcare providers seeking to reduce glycemic risk, improve safety, and support overburdened clinical teams with coordinated expertise across both outpatient and inpatient care settings. Learn more at www.glooko.com.

*Functionality will be rolled out on a market-by-market basis in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Italy, the Netherlands, Norway, Sweden, and the United Kingdom.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260310206611/en/

CONTACT: Media contacts

Glooko:

Julia Fuller

VP of Communications

[email protected]

KEYWORD: SWEDEN EUROPE

INDUSTRY KEYWORD: SOFTWARE GENERAL HEALTH PROFESSIONAL SERVICES MEDICAL DEVICES TECHNOLOGY HOSPITALS ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY DATA ANALYTICS PRACTICE MANAGEMENT HEALTH DIABETES

SOURCE: Glooko, Inc.

Copyright Business Wire 2026.

PUB: 03/10/2026 08:00 AM/DISC: 03/10/2026 08:00 AM

http://www.businesswire.com/news/home/20260310206611/en